Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Nanotechnology unlocks new pathways for targeted drug delivery

Nanotechnology unlocks new pathways for targeted drug delivery

​Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge. [More]

Impax resubmits NDA for RYTARY providing updated safety and stability information

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), announced today the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). [More]
Concise analysis of cancer drug delivery markets

Concise analysis of cancer drug delivery markets

Research and Markets (http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering. [More]
Access provides update on new formulation of anti-inflammatory drug amlexanox

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus. [More]
A novel device for inhalation drug delivery

A novel device for inhalation drug delivery

Inhalation is an increasingly important route for non-invasive drug delivery for both systemic and local applications. Control of particle size and output plays a critical role in the efficient and effective delivery of oft en expensive medications to the lung. [More]
Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors. [More]

Scientists battle against cancer with nanoballoons and lasers

Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go. [More]
BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. [More]
New mechanism uses light to activate drug-delivery inside body

New mechanism uses light to activate drug-delivery inside body

Researchers from the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, in collaboration with materials scientists, engineers and neurobiologists, have discovered a new mechanism for using light to activate drug-delivering nanoparticles and other targeted therapeutic substances inside the body. [More]
Scientists develop new substance that could simplify manufacture of cell therapy

Scientists develop new substance that could simplify manufacture of cell therapy

Scientists at The University of Nottingham have developed a new substance which could simplify the manufacture of cell therapy in the pioneering world of regenerative medicine. [More]

New device simulates gastro-intestinal tract

A breakthrough in drug testing developed by a University of Huddersfield lecturer could lead to cheaper, more effective medicines. Dr Hamid Merchant is a member of the team that has created a device which accurately simulates the gastro-intestinal tract and how it absorbs medication. [More]

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy. [More]

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States. [More]

Scientists discover simple method to measure density of engineered nanoparticles in physiological fluids

Thousands of consumer products containing engineered nanoparticles — microscopic particles found in everyday items from cosmetics and clothing to building materials — enter the market every year. Concerns about possible environmental health and safety issues of these nano-enabled products continue to grow with scientists struggling to come up with fast, cheap, and easy-to-use cellular screening systems to determine possible hazards of vast libraries of engineered nanomaterials. [More]

FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered investigational drug-device combination product for the acute treatment of migraine. [More]
Baxter plans to create two independent global healthcare companies

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets. [More]

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). [More]

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence. [More]
Egalet provides business update, reports full year 2013 financial results

Egalet provides business update, reports full year 2013 financial results

Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company. [More]
North Coast Medical announces acquisition of ActivaTek

North Coast Medical announces acquisition of ActivaTek

North Coast Medical, Inc., a manufacturer and global supplier of physical rehabilitation medical products, today announced the acquisition of Salt Lake City, Utah-based ActivaTek, Inc., a privately held manufacturer of transdermal iontophoretic devices. [More]